Read & Download your Issue of Wednesday – February  17 FNN News

WHO SCORE Global Report highlights urgent need for better data to strengthen pandemic response and improve health outcomes

• Today, 4 in 10 of the world’s deaths are unregistered and in the African region
• Two-thirds of low-income countries have established a standardized system to report causes of deaths.
• However, the SCORE Report highlights the urgent need to strengthen these systems to help the world respond to health emergencies and track progress towards global health goals.

Source: WHO

Honey and Nigella sativa against COVID-19 in Pakistan (HNS-COVID-PK): A multi-center placebo-controlled randomized clinical trial

• No definitive treatment exists for Coronavirus Disease 2019 (COVID-19). Honey and Nigella sativa (HNS) have established antiviral properties.
• Hence, this study investigated efficacy of HNS against COVID-19.
• HNS significantly improved symptoms, viral clearance and mortality in COVID-19 patients.
• Thus, HNS represents an affordable over the counter therapy and can either be used alone or in combination with other treatments to achieve potentiating effects against COVID-19.

Source: MedRxiv

Using artificial intelligence to predict which women will develop breast cancer

• A team of researchers with members from institutions in the U.S., Sweden and Taiwan has developed an artificial intelligence system for predicting breast cancer years before tumors appear.
• In this new study, the researchers used mammogram data for women who had been screened multiple times over several years.
• They trained the system to study the mammogram histories of women that had eventually developed breast cancer and then used the system to predict breast cancer risk of women in the future.

Source: Medical Express

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

• A heterologous recombinant adenovirus (rAd)-based vaccine, Gam-COVID-Vac (Sputnik V), showed a good safety profile and induced strong humoral and cellular immune responses in participants in phase 1/2 clinical trials.
• Here, they report preliminary results on the efficacy and safety of Gam-COVID-Vac from the interim analysis of this phase 3 trial.

Source: The Lancet

A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19

• Current strategies for preventing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are limited to nonpharmacologic interventions.
• Hydroxychloroquine has been proposed as a postexposure therapy to prevent coronavirus disease 2019 (Covid-19), but definitive evidence is lacking.
• Postexposure therapy with hydroxychloroquine did not prevent SARS-CoV-2 infection or symptomatic Covid-19 in healthy persons exposed to a PCR-positive case patient.

Source: NEJM

Oxford/AstraZeneca jab fails to prevent mild and moderate Covid from S African strain, study shows

• The Oxford/AstraZeneca Covid-19 vaccine does not appear to offer protection against mild and moderate disease caused by the viral variant first identified in South Africa, according to a study.
• Although none of the more than 2,000 mainly healthy and young patients in the study died or was hospitalised, the findings, which have not yet been peer reviewed, could complicate the race to roll out vaccines as new strains emerge.

Source: Financial Times

• Read more from FADIC Blog, with many articles with evidence based articles.
• Learn More Through FADIC® – Online Programs & Mini-Courses.
• Listen Now to FADIC Podcast focusing on varieties of pharmacist perspectives in specialties.
• Read More Now about FADIC Pharmacy Events to get more Experience.

Course Copyrights:

All Courses is meant for SINGLE user use only.
If more than one person acceced this course, they will be BLOCKED Forever.

Why FADIC 2021 Clinical Research E-News ?

• It helps to keep up with the literature!
• Provide you with the Updated with the latest in your clinical practice. Wherever you are, and Whenever you need!
• Help you to share in the advance in clinical career. In addition to adding an impressive image to the pharmacists all-around!

Subscribe to FADIC 2021 Clinical Research FNN E-News, for a publication of News

Read & Download FNN Issue 8 of April 2020 FNN News